SANOFIPharmaceuticals
Sanofi India Limited — Cash Flow Statement
₹3209.70
-3.82%
Sanofi India Limited Cash Flow Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Free Cash Flow | 425.10 Cr | 196.10 Cr | 376.50 Cr | 535.80 Cr | — |
| Capital Expenditure | -36.40 Cr | -34.30 Cr | -22.20 Cr | -23.00 Cr | — |
| End Cash Position | 283.80 Cr | 394.50 Cr | 1.00K Cr | 1.54K Cr | — |
| Other Cash Adjustment Outside Changein Cash | -160.60 Cr | — | — | — | — |
| Beginning Cash Position | 394.50 Cr | 1.00K Cr | 1.54K Cr | 1.20K Cr | — |
| Changes In Cash | 49.90 Cr | -610.40 Cr | -533.10 Cr | 340.60 Cr | — |
| Financing Cash Flow | -392.40 Cr | -878.30 Cr | -1.58K Cr | -849.00 Cr | — |
| Interest Paid Cff | -1.50 Cr | -1.70 Cr | -1.70 Cr | -1.80 Cr | — |
| Cash Dividends Paid | -384.60 Cr | -868.30 Cr | -1.57K Cr | -840.60 Cr | — |
| Investing Cash Flow | -19.20 Cr | 37.50 Cr | 650.90 Cr | 630.80 Cr | — |
| Interest Received Cfi | 16.60 Cr | 47.50 Cr | 58.90 Cr | 63.10 Cr | — |
| Net PPE Purchase And Sale | -35.80 Cr | -10.00 Cr | 13.10 Cr | 14.80 Cr | — |
| Sale Of PPE | 0.60 Cr | 24.30 Cr | 35.30 Cr | 37.80 Cr | — |
| Purchase Of PPE | -36.40 Cr | -34.30 Cr | -22.20 Cr | -23.00 Cr | — |
| Operating Cash Flow | 461.50 Cr | 230.40 Cr | 398.70 Cr | 558.80 Cr | — |
| Taxes Refund Paid | -97.40 Cr | -241.30 Cr | -260.70 Cr | -284.90 Cr | — |
| Change In Working Capital | -28.60 Cr | -349.00 Cr | -45.60 Cr | 68.10 Cr | — |
| Change In Other Current Liabilities | 6.10 Cr | -13.50 Cr | 18.10 Cr | -4.00 Cr | — |
| Change In Other Current Assets | -128.30 Cr | 13.40 Cr | -5.70 Cr | 27.60 Cr | — |
| Change In Payable | 166.20 Cr | -66.90 Cr | -28.00 Cr | 67.10 Cr | — |
| Change In Inventory | 68.70 Cr | -255.80 Cr | -31.40 Cr | -33.60 Cr | — |
| Change In Receivables | -127.00 Cr | 0.60 Cr | 20.60 Cr | 1.20 Cr | — |
| Other Non Cash Items | -15.10 Cr | -47.10 Cr | -57.20 Cr | -61.30 Cr | — |
| Stock Based Compensation | 1.20 Cr | 6.10 Cr | 2.10 Cr | 6.10 Cr | — |
| Provisionand Write Offof Assets | 0.70 Cr | -1.20 Cr | -1.40 Cr | 1.60 Cr | — |
| Depreciation And Amortization | 38.20 Cr | 39.60 Cr | 41.90 Cr | 66.70 Cr | — |
| Amortization Cash Flow | 1.20 Cr | 0.70 Cr | — | — | — |
| Depreciation | 37.00 Cr | 38.90 Cr | 41.90 Cr | 66.70 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.60 Cr | -0.40 Cr | 2.30 Cr | 0.70 Cr | — |
| Gain Loss On Sale Of PPE | -0.50 Cr | -21.80 Cr | -31.80 Cr | -6.60 Cr | — |
| Net Income From Continuing Operations | 562.40 Cr | 845.50 Cr | 864.30 Cr | 1.26K Cr | — |
| Gain Loss On Sale Of Business | — | 0.00 | -118.10 Cr | -489.20 Cr | — |
| Effect Of Exchange Rate Changes | — | — | 0.00 | 0.00 | 0.00 |
| Net Business Purchase And Sale | — | — | 133.90 Cr | 552.90 Cr | 239.40 Cr |
| Sale Of Business | — | — | 133.90 Cr | 552.90 Cr | 239.40 Cr |
| Net Other Investing Changes | — | — | — | 10.50 Cr | 0.40 Cr |
| Gain Loss On Investment Securities | — | — | — | -6.60 Cr | 2.80 Cr |
| Common Stock Dividend Paid | — | — | — | — | -803.80 Cr |
| Capital Expenditure Reported | — | — | — | — | -41.40 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sanofi India Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.